Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead compound, AEOL 10150, is entering human clinical trials in oncology where it is used in combination with radiation therapy. AEOL 10150 had been tested in two Phase-I clinical trials. AEOL 10150 is a metalloporphyrin designed to neutralize reactive oxygen and nitrogen species. The compound is also being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (pulmonary acute radiation syndrome or Lung-ARS), as well as the gastrointestinal sub-syndrome of acute radiation syndrome (GI-ARS). It is also being developed for use as a countermeasure for exposure to chemical vesicants, such as chlorine gas and sulfur mustard gas. Additionally, Aeolus is developing AEOL 10150 for oncology indications, where it is used in combination with radiation and chemotherapy.